hat
Anjeneral, dwòg la pouse de bouton prensipal yo mantal ki responsab pou fè pwomosyon dezi seksyèl pandan y ap inibite nerotransmeteur yo ki responsab pou siprime enterè seksyèl nan fanm yo. Te dwòg sa a prezante nan mache a tounen nan 2015 apre FDA a apwouve li pou tretman an nan akeri HSDD nan fanm.
eng
Generally, the drug pushes down the two main mental buttons that are liable for promoting sexual desires while inhibiting the neurotransmitters that are responsible for suppressing the sexual interest in women. This drug was introduced in the market back in 2015 after the FDA approved it for the treatment of acquired HSDD in women.